Pfizer recalls 28 lots of branded, generic oral contraceptive
NEW YORK — A possible pill mix-up has prompted Pfizer to recall more than two dozen lots of a prescription contraceptive drug, the drug maker said.
Pfizer announced the voluntary nationwide recall of 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 additional lots of the drug’s generic version. Pfizer manufactured and packaged the drugs, while Akrimax Pharmaceuticals commercialized them, and they were sold under the Akrimax brand.
The company said an investigation found that some blister packs of the drugs may contain an inexact count of inert or active ingredient tablets and that the tablets may not be in the correct sequence. The packaging error could leave women without adequate contraception and put them at risk of unintended pregnancy, the company said.
Lilly Diabetes donates diabetes camp scholarships
INDIANAPOLIS and ALEXANDRIA, Va. — Through a collaboration with the American Diabetes Association, the diabetes division of drug maker Eli Lilly has committed to send 89 children to diabetes camp this summer.
Lilly Diabetes said it donated the camp scholarships — a fund totaling $89,000 — to the American Diabetes Association’s 2012 camp scholarship fund. More than 400 diabetes camping programs exist worldwide serving approximately 30,000 youth with diabetes and their families, Lilly Diabetes said.
"Diabetes camps provide education on diabetes management and personal development that often lead to newfound confidence for many campers. Campers who may not have taken charge of their care before, can begin to feel empowered and eager to learn more about their own health and well-being," Lilly Diabetes VP Steve Sugino said. "Invaluable experiences like these are just a few of the many reasons that Lilly Diabetes supports diabetes camps through our collaboration with the American Diabetes Association."
FDA approves new indication for Novartis’ Gleevec
SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Novartis that is designed to prevent tumors in the gastrointestinal tract from recurring after surgical removal, the agency said.
The FDA approved Novartis’ Gleevec (imatinib) for adults who have had gastrointestinal stromal tumors, or GIST, removed. The drug was specifically approved for people whose tumors are known as CD117-positive, which includes 95% of all GIST tumors.
The drug was originally approved in 2001 for a type of leukemia.